Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 1.36
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, reasonably priced on
Data is available to registered users only
Target Price
Buy
Sell